Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2024

Open Access 13-01-2024 | Psoriatic Arthritis | REVIEW ARTICLE

The Saudi consensus recommendations for the management of psoriatic arthritis (2023)

Authors: Ibrahim Abdulrazag Al-Homood, Nayef Al Ghanim, Mohammad Ibrahim Ahmad Fatani, Albader Hamza Hussein, Abdulaziz Mohammed Alolaiwi, Abdullah Abualiat, Eman Alqurtas, Bedor Abdullah Abdulrahman Alomari, Amr Mohammad Khardaly, Khalidah Ahmed Owdetallah Alenzi, Rayan G. Albarakati, Hajer Yousef Almudaiheem, Ahmed Al-Jedai, Maysa Tariq Yousef Eshmawi

Published in: Clinical Rheumatology | Issue 3/2024

Login to get access

Abstract

Psoriatic arthritis (PsA) is a complex inflammatory disease characterized by musculoskeletal and non-musculoskeletal manifestations. It is a distinct disease entity at the interface between rheumatology and dermatology, making it challenging to manage. The diverse clinical presentation and severity of PsA require a multidisciplinary approach for optimal care. Early diagnosis and management are necessary to improving quality of life for patients. In Saudi Arabia, there is currently no unified national consensus on the best practices for managing PsA. This lack of consensus leads to debate and uncertainty in the treatment of the disease, resulting in over or under prescribing of biological agents. To address this issue, a multidisciplinary work group was formed by the Saudi Ministry of Health. This group, consisting of dermatologists, rheumatologists, and pharmacists, aimed to develop evidence-based consensus recommendations for he use and monitoring of biological therapy in PsA management. The work group conducted five consensus workshops between December 2021 to March 2022. Using the nominal group technique, they discussed various aspects of PsA management, including eligibility criteria for biological treatment, monitoring of disease activity, treatment goals, screening, precautions, and management of PsA with biologic therapies. The group also considered special considerations for patients with comorbidities, pregnant and lactating women, as well as pediatric and adolescent populations. The resulting consensus document provides recommendations that are applicable to the Saudi setting, taking into account international guidelines and the specific needs of PsA patients in the country. The consensus document will be regularly updated to incorporate new data and therapeutic agents as they become available.
Key Points
• In Saudi Arabia, there is a lack of unified national consensus on the optimal management of PsA, therefore, this article aims to provide up-to-date evidence-based consensus recommendations for the optimal use and monitoring of biologic therapy in the management of PsA in Saudi Arabia.
• The consensus development process was undertaken by a multidisciplinary work group of 13 experts, including two dermatologists, six rheumatologists, and five pharmacists.
• There is more than one disease activity tool used in PsA disease, depending on the disease domain – peripheral arthritis Disease Activity Index in Psoriatic Arthritis (DAPSA) or Minimal Disease Activity (MDA), axial PsA Ankylosing Spondylitis Disease Activity Score (ASDAS), and dactylitis and enthesitis MDA.
• The main goal of therapy in all patients with PsA is to achieve the target of remission, or alternatively, low disease activity in all disease domains and improve quality of life (QoL).
Literature
1.
2.
Brockbank J, Gladman D (2002) Diagnosis and management of psoriatic arthritis. Drugs 62(17):2447–2457PubMedCrossRef
3.
Scotti L et al (2018) Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum 48(1):28–34PubMedCrossRef
4.
Bedaiwi M et al (2019) Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East. Rheumatol Int 39(8):1321–1329PubMedCrossRef
5.
Alrubaiaan MT, Alsulaiman SA, Alqahtani A, Altasan AN, Almehrij FO, Alrashid A, Mohamed OL (2023) Prevalence and clinical predictors of psoriatic arthritis in saudi patients with psoriasis: a single-center retrospective cohort study. Cureus 15(10):e46632. https://​doi.​org/​10.​7759/​cureus.​46632
6.
Elnady B et al (2019) Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years. Clin Rheumatol 38(6):1627–1635PubMedCrossRef
7.
8.
Cassell SE et al (2007) The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 34(1):123–129PubMed
9.
Abbouda A et al (2017) Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features. Semin Ophthalmol 32(6):715–720PubMedCrossRef
10.
11.
Orbai AM et al (2017) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 76(4):673–680PubMedCrossRef
12.
Eder L et al (2016) The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol 68(4):915–923PubMedCrossRef
13.
Ritchlin CT et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387–1394PubMedCrossRef
14.
Abdulghani M et al (2011) Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement. J Int Med Res 39(5):1573–1588PubMedCrossRef
15.
Taylor W et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673PubMedCrossRef
16.
Gossec L et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700–712PubMedCrossRef
17.
Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53PubMedCrossRef
18.
Rohekar S et al (2015) 2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J Rheumatol 42(4):654–64PubMedCrossRef
19.
Freites Nuñez D et al (2021) Factors associated with health-related quality of life in psoriatic arthritis patients: A longitudinal analysis. Rheumatol Ther 8(3):1341–1354PubMedPubMedCentralCrossRef
20.
Al Rayes H et al (2022) Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis. Rheumatol Int 42(3):391–401PubMedCrossRef
21.
Coates LC et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071PubMedCrossRef
22.
Kavanaugh A et al (2020) GRAPPA treatment recommendations: updates and methods. J Rheumatol Suppl 96:41–45PubMedCrossRef
23.
Gossec L et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510PubMedCrossRef
24.
Coates LC et al (2013) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology 52(10):1754–1757 (Oxford)PubMedCrossRef
25.
Flint J et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55(9):1693–1697 (Oxford)PubMedCrossRef
26.
Flint J et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55(9):1693–1697PubMedCrossRef
27.
Horton JN (1980) Nominal group technique. A method of decision-making by committee. Anaesthesia 35(8):811–4PubMedCrossRef
28.
29.
Sarzi-Puttini P et al (2001) The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 19(1 Suppl 22):S17-20PubMed
30.
31.
McInnes IB et al (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73(2):349–356PubMedCrossRef
32.
Mease PJ et al (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76(1):79–87PubMedCrossRef
33.
Deodhar A et al (2018) Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 391(10136):2213–2224PubMedCrossRef
34.
Kristensen LE et al (2022) Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis 81(2):225–231PubMedCrossRef
35.
Gladman DD et al (2007) Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56(2):476–488PubMedCrossRef
36.
37.
Mease PJ et al (2021) Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatol Ther 8(2):903–919PubMedPubMedCentralCrossRef
38.
Mourad A, Gniadecki R (2020) Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis. J Rheumatol 47(1):59–65PubMedCrossRef
39.
Schafer PH et al (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159(4):842–855PubMedCrossRef
40.
41.
Mease PJ (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 63(Suppl 11):S64-85 (Hoboken)
42.
van der Heijde D et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991PubMedCrossRef
43.
Carneiro S et al (2021) Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis. Adv Rheumatol 61(1):69PubMedCrossRef
44.
Machado PM, Landewé R, Heijde DV (2018) Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis 77(10):1539–1540PubMedCrossRef
45.
46.
Braun J et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62(9):817–824PubMedPubMedCentralCrossRef
47.
Holroyd CR et al (2019) The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary. Rheumatology 58(2):220–226 (Oxford)PubMedCrossRef
48.
Thrastardottir T, Love TJ (2018) Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review. Rheumatol Int 38(8):1385–1397PubMedCrossRef
49.
Haddad A et al (2016) The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts. J Rheumatol 43(2):362–366PubMedCrossRef
50.
Cantini F et al (2014) HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol 2014:926836PubMedPubMedCentralCrossRef
51.
52.
Wolk R et al (2017) Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. J Clin Lipidol 11(5):1243–1256PubMedCrossRef
53.
Tubach F et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60(7):1884–1894PubMedPubMedCentralCrossRef
54.
55.
Bélard E et al (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 17(11):2340–2349PubMedCrossRef
56.
Ruan Q et al (2016) Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis. Clin Rheumatol 35(2):417–425PubMedCrossRef
57.
Sterling TR et al (2020) Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 69(1):1–11PubMedPubMedCentralCrossRef
58.
59.
Dressler C et al (2019) Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. J Eur Acad Dermatol Venereol 33(7):1249–1260PubMedCrossRef
60.
61.
Mease PJ et al (2021) Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology 60(5):2109–2121 (Oxford)PubMedPubMedCentralCrossRef
62.
McInnes IB et al (2019) Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open 5(2):e000990PubMedPubMedCentralCrossRef
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
Menter A et al (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4):1029–1072PubMedCrossRef
73.
74.
Ayan G et al (2023) Pharmacologic treatment strategies in psoriatic arthritis. Clin Ther 45(9):826–840PubMedCrossRef
75.
Baraliakos X et al (2021) Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 80(5):582–590PubMedCrossRef
76.
Moverley A et al (2015) A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)). Clin Rheumatol 34(8):1407–1412PubMedCrossRef
77.
Cantini F et al (2008) Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 47(6):872–876 (Oxford)PubMedCrossRef
78.
Araujo EG et al (2015) High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis 74(4):655–660MathSciNetPubMedCrossRef
79.
Chimenti MS et al (2013) Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients’ clinical characteristics leading to disease relapse. Int J Immunopathol Pharmacol 26(3):833–838PubMedCrossRef
80.
Janta I et al (2015) Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. Clin Rheumatol 34(5):935–942PubMedCrossRef
81.
Ye W, Tucker LJ, Coates LC (2018) Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs 78(16):1705–1715PubMedCrossRef
82.
González-Álvaro I et al (2015) Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology 54(7):1200–1209 (Oxford)PubMedCrossRef
83.
Mandl P et al (2015) EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 74(7):1327ADSPubMedCrossRef
84.
Fagerli KM et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73(1):132–137PubMedCrossRef
85.
Mease PJ et al (2019) Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized Controlled Phase III Trial. Arthritis Rheumatol 71(7):1112–1124PubMedPubMedCentralCrossRef
86.
Glintborg B et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65(5):1213–1223PubMedCrossRef
87.
Berman J et al (2021) AB0551 TREATMENT WITH IXEKIZUMAB FOLLOWING SECUKINUMAB FAILURE IN PATIENTS WITH PSORIATIC ARTHRITIS: REAL-LIFE EXPERIENCE FROM A RESISTANT POPULATION. Ann Rheum Dis 80(Suppl 1):1309–1310CrossRef
88.
Holroyd CR et al (2018) The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology 58(2):e3–e42CrossRef
89.
90.
Yang K, Oak ASW, Elewski BE (2021) Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol 22(2):173–192PubMedCrossRef
91.
92.
Gladman DD et al (2018) Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies. RMD Open 4(1):e000669PubMedPubMedCentralCrossRef
93.
Nash P et al (2018) Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77(5):690–698PubMedCrossRef
94.
Wells AF et al (2018) Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology 57(7):1253–1263 (Oxford)PubMedPubMedCentralCrossRef
95.
Kavanaugh A et al (2019) Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis. Arthritis Res Ther 21(1):118PubMedPubMedCentralCrossRef
96.
97.
98.
Patel S, Kumthekar A (2022) Psoriatic arthritis: the influence of co-morbidities on drug choice. Rheumatol Ther 9(1):49–71PubMedCrossRef
99.
Askling J et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7):1986–1992PubMedCrossRef
100.
Dixon WG et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522–528PubMedCrossRef
101.
Fonseca JE et al (2006) Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port 31(3):247–253PubMed
102.
Gómez-Reino JJ et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122–2127PubMedCrossRef
103.
Keane J et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104PubMedCrossRef
104.
Nast A et al (2017) European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 31(12):1951–1963PubMedCrossRef
105.
Evangelatos G et al (2020) Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 12:1759720X20930116
106.
Lee YH, Bae SC, Song GG (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31(1):118–121PubMed
107.
Lee YH, Bae SC, Song GG (2013) Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis 16(5):527–531PubMedCrossRef
108.
Pérez-Alvarez R et al (2011) Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 90(6):359–371 (Baltimore)PubMedCrossRef
109.
Urata Y et al (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21(1):16–23PubMedCrossRef
110.
Chen YM et al (2015) A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis 74(3):626–627PubMedCrossRef
111.
EASL clinical practice guidelines (2012) Management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185CrossRef
112.
Reddy KR et al (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(1):215–9; quiz e16–7
113.
Chiu HY et al (2013) The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 169(6):1295–1303PubMedCrossRef
114.
115.
Akiyama S, Cotter TG, Sakuraba A (2021) Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 27(19):2312–2324PubMedPubMedCentralCrossRef
116.
Duncan JR, Orlowski TJ, Elewski BE (2019) Safety of guselkumab in hepatitis B virus infection. Dermatol Online J 25(10):13030/qt47h636rx
117.
Iannone F et al (2014) Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol 41(2):286–292PubMedCrossRef
118.
Costa L et al (2014) Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33(2):273–276PubMedCrossRef
119.
Temel T et al (2015) The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections. Int J Rheum Dis 18(1):40–45PubMedCrossRef
120.
Cavazzana I et al (2008) Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8(2):104–106PubMedCrossRef
121.
Pappas DA et al (2019) Therapy with biologic agents after diagnosis of solid malignancies: results from the corrona registry. J Rheumatol 46(11):1438–1444PubMedCrossRef
122.
Nast A et al (2021) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 35(2):281–317PubMedCrossRef
123.
Smith CH et al (2017) British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 177(3):628–636PubMedCrossRef
124.
Álvaro-Gracia JM et al (2021) Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review. Rheumatol Ther 8(1):17–40PubMedCrossRef
125.
Havrdová E et al (2016) Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol 263(7):1287–1295PubMedCrossRef
126.
van Vollenhoven RF et al (2018) Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392(10155):1330–1339PubMedCrossRef
127.
Micheroli R et al (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19(1):164PubMedPubMedCentralCrossRef
128.
129.
Clowse ME et al (2017) Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 76(11):1890–1896PubMedCrossRef
130.
Mariette X et al (2018) Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 77(2):228–233PubMedCrossRef
131.
Ringold S et al (2019) 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res 71(6):717–734 (Hoboken)CrossRef
132.
Huemer C et al (2002) Patterns of joint involvement at onset differentiate oligoarticular juvenile psoriatic arthritis from pauciarticular juvenile rheumatoid arthritis. J Rheumatol 29(7):1531–1535PubMed
133.
Lewkowicz D, Gottlieb AB (2004) Pediatric psoriasis and psoriatic arthritis. Dermatol Ther 17(5):364–375PubMedCrossRef
134.
135.
Menter A et al (2020) Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol 82(1):161–201PubMedCrossRef
136.
Guzman J et al (2015) The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 74(10):1854–1860PubMedCrossRef
137.
Sobel RE et al (2014) Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. Pediatr Rheumatol Online J 12:29PubMedPubMedCentralCrossRef
138.
van Rossum MA et al (2007) Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 66(11):1518–1524PubMedPubMedCentralCrossRef
139.
Ruperto N et al (2021) Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398(10315):1984–1996PubMedCrossRef
140.
Ruperto N et al (2021) LB0004 efficacy and safety of secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: primary results from a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (junipera). Ann Rheum Dis 80(Suppl 1):201–202CrossRef
141.
van der Heijde D et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 394(10214):2108–2117PubMedCrossRef
142.
Heijstek MW et al (2013) Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 309(23):2449–2456PubMedCrossRef
143.
De Felice KM, Kane S (2021) Safety of anti-TNF agents in pregnancy. J Allergy Clin Immunol 148(3):661–667PubMedCrossRef
Metadata
Title
The Saudi consensus recommendations for the management of psoriatic arthritis (2023)
Authors
Ibrahim Abdulrazag Al-Homood
Nayef Al Ghanim
Mohammad Ibrahim Ahmad Fatani
Albader Hamza Hussein
Abdulaziz Mohammed Alolaiwi
Abdullah Abualiat
Eman Alqurtas
Bedor Abdullah Abdulrahman Alomari
Amr Mohammad Khardaly
Khalidah Ahmed Owdetallah Alenzi
Rayan G. Albarakati
Hajer Yousef Almudaiheem
Ahmed Al-Jedai
Maysa Tariq Yousef Eshmawi
Publication date
13-01-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 3/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-06867-x

Other articles of this Issue 3/2024

Clinical Rheumatology 3/2024 Go to the issue

CLINICAL IMAGE

Hypoglossal nerve palsy due to basilar impression in rheumatoid arthritis

Review Article

Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review

CASE BASED REVIEW

Intrathecal injection of methotrexate and dexamethasone for vasculitis granuloma of the fourth ventricle: a case report and literature review

ORIGINAL ARTICLE

Effects of disease-modifying anti-rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: a systematic review and meta-analysis

ORIGINAL ARTICLE

The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients

Original Article

Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits